Bosley leaving Editas as CRISPR company moves toward clinic

Editas Medicine Inc. (NASDAQ:EDIT) said Katrine Bosley is stepping down as president and CEO, effective March 1. Cynthia Collins, a director since December, will be interim CEO

Read the full 274 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE